Connection

Michael Kleines to Janus Kinase Inhibitors

This is a "connection" page, showing publications Michael Kleines has written about Janus Kinase Inhibitors.
Connection Strength

0.138
  1. Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis. Eur J Haematol. 2020 Nov; 105(5):655-658.
    View in: PubMed
    Score: 0.138
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.